Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals director Gautam Patel increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units into the same number of shares of Class A Common Stock at a stated price of $0.00 per share. After this exercise, he directly owned 1,643,963 shares of Class A Common Stock. On May 6, 2026, he was also granted 19,824 restricted stock units, each representing a contingent right to receive one share of Class A Common Stock, which vest under the company’s director vesting schedule linked to the first annual meeting and one-year anniversary of grant.
Amneal Pharmaceuticals director John Kiely reported compensation-related equity activity. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares at a stated price of $0.00 per share. The Form 4 also shows a grant of 19,824 restricted stock units on May 6, 2026, each representing a right to receive one share of Class A Common Stock. After these transactions, Kiely directly owns 260,252 Class A Common Stock shares, with no remaining restricted stock units reported in this filing.
Amneal Pharmaceuticals director Ted C. Nark increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares at a price of $0 per share, bringing his direct holdings to 325,848 shares.
The exercised units were part of a 34,819-unit award granted on May 6, 2025 that vested on May 7, 2026. On May 6, 2026, he also received a new grant of 19,824 restricted stock units, each representing a contingent right to one share of Class A Common Stock, with vesting tied to the company’s director vesting schedule.
Amneal Pharmaceuticals director Paul M. Meister reported equity compensation moves involving the company’s Class A Common Stock. On May 7, 2026, he exercised 48,747 Restricted Stock Units, receiving the same number of Class A shares, bringing his direct holdings to 832,800 shares.
Separately, on May 6, 2026, he received a new grant of 30,837 Restricted Stock Units, each representing a contingent right to one share of Class A Common Stock. A footnote states an earlier grant of 48,747 RSUs on May 6, 2025 vested on May 7, 2026.
Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake through stock-based compensation activity. He exercised 34,819 restricted stock units into the same number of shares of Class A Common Stock and did not sell any shares. Following this exercise, he directly owns 320,804 shares. In a separate transaction, he also received a grant of 19,824 new restricted stock units, each representing a contingent right to receive one share of Class A Common Stock.
Amneal Pharmaceuticals, Inc. reported stronger results for the quarter ended March 31, 2026. Net revenue rose to $722.5 million from $695.4 million, while net income jumped to $78.0 million from $24.6 million. EPS for Class A shareholders increased to $0.20 basic versus $0.04 a year earlier as gross margin expanded, helped by lower cost of goods and reduced amortization.
The Specialty segment drove much of the growth with higher sales of CREXONT, BREKIYA autoinjector and UNITHROID, while Affordable Medicines also improved and AvKARE declined modestly. Amneal remains highly leveraged with $2.69 billion of term loans and senior notes and a stockholders’ deficiency of $46.0 million.
Cash, cash equivalents and restricted cash fell to $204.4 million from $312.9 million, partly due to $38.8 million of tax receivable agreement payments and initial opioid settlement installments. The company finalized its Nationwide Opioids Settlement Agreement and recorded approximately $79.3 million in related liabilities. After quarter-end, Amneal agreed to acquire Kashiv BioSciences for $375 million in cash, 28.9 million Class A shares and up to $350 million in contingent payments, and signed a major mirabegron supply and distribution deal with MSN Laboratories.
Amneal Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026. Stockholders elected all 11 director nominees, including Deb Autor, Chintu Patel, Chirag Patel and Gautam Patel, to serve until the 2027 annual meeting and until their successors are elected and qualified.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. In addition, they ratified the selection of Ernst & Young LLP as Amneal’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Amneal Pharmaceuticals reported strong first quarter 2026 results. Net revenue was $722.5 million, up 4% from $695.4 million a year earlier, driven by 23% Specialty growth and 2% Affordable Medicines growth, partly offset by a 4% AvKARE decline.
Net income attributable to Amneal rose to $62.3 million from $12.2 million, while adjusted EBITDA increased 19% to $202.0 million. Diluted EPS was $0.19 versus $0.04, and adjusted diluted EPS was $0.27 versus $0.21, reflecting higher revenue and improved gross margins.
The company affirmed its increased 2026 outlook, guiding to net revenue of $3.05–$3.15 billion, adjusted EBITDA of $740–$770 million, adjusted diluted EPS of $0.95–$1.05, operating cash flow of $350–$400 million, and about $110 million in capital expenditures.
BlackRock, Inc. reports beneficial ownership of 7.6% of Amneal Pharmaceuticals, Inc. common stock, holding 24,121,119 shares as of 03/31/2026. The filing states these shares are attributed to certain "Reporting Business Units" of BlackRock, in accordance with SEC Release No. 34-39538 (January 12, 1998).
Amneal Pharmaceuticals agreed to acquire 100% of Kashiv BioSciences, paying $375 million in cash and issuing 28,942,108 Class A shares at closing, plus up to $350 million in regulatory milestone payments and potential royalties based on future gross profits.
The deal, expected to close in the second half of 2026 subject to shareholder and regulatory approvals, is intended to create a scaled, fully integrated global biosimilars platform. An independent conflicts committee approved the transaction terms and will recommend that stockholders approve the stock issuance and Purchase Agreement.
Alongside the deal, Amneal reported strong preliminary Q1 2026 results, with net revenue of $723 million, net income of $78 million and adjusted EBITDA of $202 million, and raised 2026 guidance for adjusted EBITDA, adjusted diluted EPS and operating cash flow.